Highlighting Ongoing Clinical Trials in CML From ASH
Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
EP: 1.How Ponatinib Factors into the Treatment of a Type of Leukemia
EP: 2.The Implications of CML Data From ASH, And Important Takeaways for Providers
EP: 3.Highlighting Ongoing Clinical Trials in CML From ASH
EP: 4.Phase 3 ASCEMBL Study Demonstrates Superiority of Asciminib in CML-CP
EP: 5.Superiority of Asciminib in CML-CP Is a ‘Win-Win’ for Patients
EP: 6.Asciminib Offers Additional Tool to Treat CML-CP
EP: 7.Ongoing Studies in CML-CP Offer Hope to Future Treatments
EP: 8.Recap: Moffitt and Mayo Face-Off in CML Treatment Updates From ASH
During a post-Face-Off interview, Kendra Sweet, MD, discussed the use of futibatinib (Lytgobi) in patients with chronic myeloid leukemia (CML).
Transcript:
[The trial with futibatinib (Lytgobi)] is ongoing. It’s a small study, with 43 patients who’ve been enrolled, but it is an active drug. That’s a study that's going to be harder to enroll in because the drug doesn’t have activity in T315I. We have a lot of drugs in CML now, and they are all very active drugs. Finding a place to position that drug will be a challenge, but I think it will be interesting to see where that falls in the sequence of all these other agents. Depending on the [adverse] effect profile and the toxicity of that drug, that’s where it could potentially be impactful if it has a tall, tolerable [adverse] effect profile. I think then it could be a valuable drug, but there are a lot more patients that need to be treated with it before we start to move that into any kind of standard of care.
